Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The company provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. Medicago was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada.